Protein Science Sheba protein
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print June 3, 2005, 10.1110/ps.051347405
Protein Science (2005), 14:1870-1878. Published by Cold Spring Harbor Laboratory Press. Copyright © 2005 The Protein Society
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ps.051347405v1
14/7/1870    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kagan, R. M.
Right arrow Articles by Ramnarayan, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kagan, R. M.
Right arrow Articles by Ramnarayan, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir

Ron M. Kagan1, Mark D. Shenderovich2, Peter N.R. Heseltine1 and Kal Ramnarayan2

1 Department of Infectious Diseases, Quest Diagnostics Inc., San Juan Capistrano, California 92675, USA
2 Cengent Therapeutics Inc., San Diego, California 92127, USA

(RECEIVED January 10, 2005; FINAL REVISION April 10, 2005; ACCEPTED April 11, 2005)

We have identified a rare HIV-1 protease (PR) mutation, I47A, associated with a high level of resistance to the protease inhibitor lopinavir (LPV) and with hypersusceptibility to the protease inhibitor saquinavir (SQV). The I47A mutation was found in 99 of 112,198 clinical specimens genotyped after LPV became available in late 2000, but in none of 24,426 clinical samples genotyped from 1998 to October 2000. Phenotypic data obtained for five I47A mutants showed unexpected resistance to LPV (86- to >110-fold) and hypersusceptibility to SQV (0.1- to 0.7-fold). Molecular modeling and energy calculations for these mutants using our structural phenotyping methodology showed an increase in the binding energy of LPV by 1.9–3.1 kcal/mol with respect to the wild type complex, corresponding to a 20- to >100-fold decrease in binding affinity, consistent with the observed high levels of LPV resistance. In the WT PR–LPV complex, the Ile 47 side chain is positioned close to the phenoxyacetyl moiety of LPV and its van der Waals interactions contribute significantly to the ligand binding. These interactions are lost for the smaller Ala 47 residue. Calculated binding energy changes for SQV ranged from –0.4 to –1.2 kcal/mol. In the mutant I47A PR–SQV complexes, the PR flaps are packed more tightly around SQV than in the WT complex, resulting in the formation of additional hydrogen bonds that increase binding affinity of SQV consistent with phenotypic hypersusceptibility. The emergence of mutations at PR residue 47 strongly correlates with increasing prescriptions of LPV (Spearman correlation rs=0.96, P<.0001).

Keywords: HIV protease inhibitors; lopinavir; saquinavir; drug resistance; molecular modeling; binding energy; structure-based phenotyping

Abbreviations: 3D, three-dimensional • HIV-1, human immunodeficiency virus type 1 • ARV, anti-retroviral • APV, amprenavir • IDV, indinavir • LPV, lopinavir • LPV/r, lopinavir coadministered with ritonavir • NFV, nelfinavir • SQV, saquinavir • PI, protease inhibitor • PR, protease • WT, wild type.

Article published online ahead of print. Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.051347405.

Reprint requests to: Ron M. Kagan, Department of Infectious Diseases, Quest Diagnostics Inc., 33608 Ortega Highway, San Juan Capistrano, CA 92675, USA; e-mail: kaganr{at}questdiagnostics.com; fax: (949) 728-4022.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Protein Sci.Home page
K. G. Saskova, M. Kozisek, M. Lepsik, J. Brynda, P. Rezacova, J. Vaclavikova, R. M. Kagan, L. Machala, and J. Konvalinka
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir
Protein Sci., September 1, 2008; 17(9): 1555 - 1564.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Kozisek, K. G. Saskova, P. Rezacova, J. Brynda, N. M. van Maarseveen, D. De Jong, C. A. Boucher, R. M. Kagan, M. Nijhuis, and J. Konvalinka
Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region
J. Virol., June 15, 2008; 82(12): 5869 - 5878.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Masse, X. Lu, T. Dekhtyar, L. Lu, G. Koev, F. Gao, H. Mo, D. Kempf, B. Bernstein, G. J. Hanna, et al.
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3075 - 3080.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
H. E. Klei, K. Kish, P.-F. M. Lin, Q. Guo, J. Friborg, R. E. Rose, Y. Zhang, V. Goldfarb, D. R. Langley, M. Wittekind, et al.
X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir
J. Virol., September 1, 2007; 81(17): 9525 - 9535.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by The Protein Society.